Adra1B Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Attribute | Value | [1]
|-----------|-------|
| Gene Symbol | ADRA1B |
| Full Name | Alpha-1B Adrenergic Receptor |
| Chromosomal Location | 5q23.3 |
| NCBI Gene ID | 147 |
| Ensembl ID | ENSG00000170175 |
| UniProt ID | P35368 |
| Gene Family | Adrenergic receptors (GPCR) |
| Protein Class | G protein-coupled receptor |
| Expression | Smooth muscle, brain, heart |
The ADRA1B gene encodes the alpha-1B adrenergic receptor (α1B-AR), a G protein-coupled receptor (GPCR) that mediates the effects of epinephrine and norepinephrine on smooth muscle contraction, cardiac function, and neuronal signaling. This receptor is one of three alpha-1 adrenergic receptor subtypes (α1A, α1B, and α1D) that belong to the larger adrenergic receptor family, which also includes the beta-adrenergic receptors. The α1B-AR plays important roles in cardiovascular regulation, blood pressure control, pupil dilation, and has emerging roles in neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD)[2].
The ADRA1B gene is located on chromosome 5q23.3 and encodes a 515-amino acid protein. The receptor contains seven transmembrane domains typical of GPCRs and couples primarily to Gq proteins, activating phospholipase C signaling pathways that lead to increased intracellular calcium and protein kinase C activation. While classically studied in the context of cardiovascular function, research over the past two decades has revealed important functions of α1B-AR in the central nervous system, including modulation of cognitive function, neuroprotection, and regulation of cerebral blood flow[3].
Alpha-1 adrenergic receptors have been targeted by several FDA-approved drugs, including prazosin, doxazosin, and terazosin, which are used to treat hypertension and benign prostatic hyperplasia. Interestingly, some epidemiological studies suggest that prazosin use may be associated with reduced risk of neurodegenerative diseases, prompting investigation of α1B-AR signaling in brain health and disease[4].
The ADRA1B gene is located on chromosome 5q23.3 and encodes a 515-amino acid protein. The receptor contains seven transmembrane domains typical of GPCRs and couples primarily to Gq proteins, activating phospholipase C signaling pathways. The protein consists of:
The ligand-binding pocket is formed within the transmembrane domains, with catecholamines (epinephrine, norepinephrine) binding to conserved residues in helices III, V, VI, and VII. The α1B-AR has distinct pharmacological properties that allow selective targeting by drug compounds.
The primary G protein coupling for α1B-AR is Gq/11:
α1B-adrenergic receptors are expressed in:
α1B-adrenergic receptors are expressed in:
| Tissue | Expression Level | Primary Function |
|---|---|---|
| Vascular Smooth Muscle | Very High | Vasoconstriction |
| Heart | Moderate | Cardiac contractility |
| Liver | Moderate | Glycogenolysis |
| Kidney | Low-Moderate | Renin secretion |
| Bladder | Moderate | Smooth muscle contraction |
| Prostate | Moderate | Smooth muscle tone |
In the central nervous system, α1B-AR is expressed in:
The brain expression pattern supports roles in cognitive function and autonomic regulation[5].
α1B-AR is implicated in AD pathophysiology through multiple mechanisms:
The locus coeruleus noradrenergic system is early affected in AD:
Studies demonstrate altered α1B-AR expression in AD brains, with some evidence suggesting both up-regulation (as compensatory mechanism) and down-regulation (as disease progression) depending on disease stage[6].
α1B-AR signaling may affect amyloid processing:
Noradrenergic signaling modulates neuroinflammation:
The anti-inflammatory effects of norepinephrine are partially mediated through α1-AR signaling, suggesting potential therapeutic benefits of α1B-AR modulation in AD[7].
In PD, α1B-adrenergic receptors may play several roles:
α1B-AR signaling may provide neuroprotection:
Some epidemiological studies suggest that prazosin use is associated with reduced PD risk, prompting investigation of α1B-AR in dopaminergic neuron survival[8].
α1B-AR may affect motor symptoms:
α1B-AR is relevant to cerebrovascular disease:
α1B-AR antagonists have been studied in stroke therapy, with mixed results. The timing and context of intervention appears critical for determining whether blockade is beneficial or harmful[9].
Recent research suggests α1B-AR involvement in tauopathies:
Studies demonstrate that prazosin can reduce tau pathology in model systems, suggesting potential therapeutic applications for AD and related disorders[10].
| Drug | Type | Clinical Use |
|---|---|---|
| Prazosin | Antagonist | Hypertension, PTSD |
| Terazosin | Antagonist | BPH |
| Doxazosin | Antagonist | Hypertension, BPH |
| Tamsulosin | Antagonist | BPH (selective) |
| Alfuzosin | Antagonist | BPH |
Prazosin and related compounds are being investigated for neurodegenerative disease:
Clinical trials are evaluating prazosin for cognitive impairment in AD and related conditions[11].
Guimaraes S, Moura D. Vascular alpha-adrenoceptors: an overview. Pharmacological Reviews. 2001. ↩︎
Zhong H, Minneman KP. Alpha1-adrenoceptor subtypes. Molecular Pharmacology. 1999. ↩︎
Clements GM, et al. Alpha1B-adrenergic receptor signaling in neuronal cells. Journal of Neurochemistry. 2001. ↩︎
Piascik MS, Perez DM. Alpha1-adrenergic receptor subtypes. Journal of Molecular Neuroscience. 2003. ↩︎
Knaus AE, et al. Alpha1-adrenergic receptors in the brain: regional distribution and function. Brain Research. 2000. ↩︎
Gomez R, et al. Alpha1-adrenoceptors in Alzheimer's disease brain. Journal of Alzheimer's Disease. 2011. ↩︎
Liu Y, et al. Noradrenergic signaling and neuroinflammation in Alzheimer's disease. Journal of Neuroinflammation. 2021. ↩︎
Sakloth P, et al. Alpha1-adrenergic receptors in Parkinson's disease: neuroprotection strategies. Movement Disorders. 2019. ↩︎
Xu Y, et al. Targeting alpha1-adrenergic receptors in stroke therapy. Stroke. 2021. ↩︎
Park J, et al. Prazosin and related compounds in tauopathies. Nature Communications. 2022. ↩︎
Su M, et al. Prazosin, an alpha1-AR antagonist, in traumatic brain injury. Neurobiology of Disease. 2023. ↩︎